Clinical Trial Update: Safety and Efficacy of HydroLenz for Vitrectomy-Induced Lens Opacities [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating HydroLenz for vitrectomy-induced lens opacities has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataract

Drugs mentioned

• HydroLenz

Snippet

Sponsor: PromiSight, LLC | Conditions: Pars Plana Vitrectomy | Phase 1 | Status: WITHDRAWN